Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials.
- DOI
- 10.1186/s12888-023-05422-3
- Published
- 2024 Jan 4
- Container
- BMC psychiatry
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12888-023-05422-3,
title = {Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials.},
author = {Müller AR and den Hollander B and van de Ven PM and Roes KCB and Geertjens L and Bruining H and van Karnebeek CDM and Jansen FE and de Wit MCY and Ten Hoopen LW and Rietman AB and Dierckx B and Wijburg FA and Boot E and Brands MMG and van Eeghen AM},
year = {2024},
journal = {BMC psychiatry},
doi = {10.1186/s12888-023-05422-3},
url = {https://doi.org/10.1186/s12888-023-05422-3}
}RIS
TY - JOUR TI - Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials. AU - Müller AR AU - den Hollander B AU - van de Ven PM AU - Roes KCB AU - Geertjens L AU - Bruining H AU - van Karnebeek CDM AU - Jansen FE AU - de Wit MCY AU - Ten Hoopen LW AU - Rietman AB AU - Dierckx B AU - Wijburg FA AU - Boot E AU - Brands MMG AU - van Eeghen AM PY - 2024 JO - BMC psychiatry DO - 10.1186/s12888-023-05422-3 UR - https://doi.org/10.1186/s12888-023-05422-3 ER -
APA
AR, M., B, D. H., PM, V. D. V., KCB, R., L, G., H, B., CDM, V. K., FE, J., MCY, D. W., LW, T. H., AB, R., B, D., FA, W., E, B., MMG, B., & AM, V. E. (2024). Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials.. BMC psychiatry. https://doi.org/10.1186/s12888-023-05422-3
Source records
- pubmed · retrieved 2026-11-10T14:56:17.275Z